Mounjaro for Weight Loss: The Evidence Behind Off-Label Tirzepatide

Why Mounjaro Is Prescribed Off-Label for Weight Loss

Tirzepatide is a single molecule sold under two brand names. The FDA approved Mounjaro in May 2022 for glycemic control in type 2 diabetes, and approved the identical compound as Zepbound in November 2023 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity [1]. When a clinician writes a Mounjaro prescription for a patient whose primary goal is weight loss rather than blood sugar control, that prescription is off-label.

This distinction matters mostly for insurance billing and pharmacy adjudication. The drug itself, the doses, the injection device, and the side-effect profile are the same. Off-label prescribing is legal, common in medicine, and in this case backed by phase 3 trial data that the FDA reviewed when it approved Zepbound [2]. The American Medical Association has affirmed that off-label prescribing is appropriate when supported by sound evidence and informed consent.

Some clinicians default to the Mounjaro NDA because payer formularies may cover it under a diabetes benefit while denying Zepbound under a pharmacy benefit that excludes anti-obesity medications. A 2024 KFF analysis found that only 25% of large employer plans covered GLP-1 receptor agonists for weight loss, while diabetes coverage was near-universal [3]. That coverage gap drives a significant share of off-label Mounjaro prescriptions written today.

How Tirzepatide Works: Dual GIP and GLP-1 Receptor Agonism

Tirzepatide activates two incretin receptors simultaneously. It binds glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors, producing effects that neither pathway achieves alone [4]. GLP-1 receptor agonism slows gastric emptying, suppresses glucagon secretion, and reduces appetite through hypothalamic signaling. GIP receptor agonism appears to amplify these effects and may independently influence fat metabolism, though the precise contribution of GIP signaling to weight loss is still being studied.

This dual mechanism separates tirzepatide from single-receptor GLP-1 agonists like semaglutide (Ozempic/Wegovy) and liraglutide (Saxenda). In preclinical models, dual agonism produced greater reductions in food intake and body weight than GLP-1 agonism alone [5]. The clinical trial results have confirmed that translation. Dr. Ania Jastreboff, an obesity medicine specialist at Yale who served as lead investigator on the SURMOUNT-1 trial, stated: "The degree of weight reduction with tirzepatide is unprecedented for a single-agent pharmacotherapy" [6].

The half-life of tirzepatide is approximately 5 days, supporting once-weekly dosing. Steady-state plasma concentrations are reached after 4 to 5 weekly doses at each escalation step, which is why the prescribing information recommends staying at each dose level for at least 4 weeks before increasing [1].

SURMOUNT-1: The Landmark Obesity Trial

SURMOUNT-1 remains the definitive trial for tirzepatide in weight management. This randomized, double-blind, placebo-controlled study enrolled 2,539 adults with a BMI of 30 or greater (or 27 or greater with at least one comorbidity) but without type 2 diabetes [6]. Participants received tirzepatide 5 mg, 10 mg, or 15 mg, or placebo, via weekly subcutaneous injection for 72 weeks alongside lifestyle counseling.

The results, published in the New England Journal of Medicine in July 2022, were striking. Mean percentage body weight change at 72 weeks was -15.0% with 5 mg, -19.5% with 10 mg, and -22.5% with 15 mg, compared to -3.1% with placebo [6]. At the 15 mg dose, 63% of participants lost at least 20% of their body weight. For context, bariatric surgery (sleeve gastrectomy) typically produces 25% to 30% weight loss at one year [7].

These were not patients selected for likelihood of response. The trial enrolled a broad population with a mean baseline BMI of 38 and a mean body weight of 104.8 kg. Participants came from 119 sites across 9 countries.

The safety profile was consistent with the GLP-1 receptor agonist class. Gastrointestinal events were the most common adverse effects: nausea occurred in 24% to 33% of tirzepatide groups versus 9% in placebo, diarrhea in 16% to 23% versus 8%, and vomiting in 9% to 13% versus 2% [6]. Most GI events were mild to moderate and occurred during dose escalation. Discontinuation due to adverse events was 4.3% to 7.1% across tirzepatide doses versus 2.6% for placebo.

SURMOUNT-2: Weight Loss in Patients With Type 2 Diabetes and Obesity

SURMOUNT-2 addressed whether tirzepatide could produce meaningful weight loss in patients who also had type 2 diabetes, a population that historically loses less weight on anti-obesity medications [8]. The trial randomized 938 adults with type 2 diabetes and a BMI of 27 or greater to tirzepatide 10 mg, 15 mg, or placebo for 72 weeks.

At 72 weeks, mean weight loss was -12.8% with 10 mg and -14.7% with 15 mg versus -3.2% with placebo [8]. These results confirmed that tirzepatide produces double-digit weight loss even in the presence of diabetes, a condition where insulin resistance and concomitant medications (particularly sulfonylureas and insulin) often blunt weight-loss outcomes.

The trial also documented a mean HbA1c reduction of 2.1 percentage points with the 15 mg dose, bringing the average participant from an HbA1c of 8.02% down to about 5.9%, which is below the diagnostic threshold for diabetes [8]. This dual efficacy on weight and glycemia is precisely why some clinicians use the Mounjaro NDA: the patient may have both conditions, and a single prescription addresses both.

SURMOUNT-3 and SURMOUNT-4: Intensive Lifestyle and Maintenance Data

SURMOUNT-3 tested whether adding tirzepatide after an initial 12-week intensive lifestyle intervention could deepen weight loss beyond what behavior change alone achieves [9]. After losing a mean of 6.9% body weight through caloric restriction and exercise, participants who then received tirzepatide 15 mg lost an additional 18.4% for a total of roughly 25% from original baseline, compared to 2.2% additional loss with placebo.

SURMOUNT-4 addressed weight regain after discontinuation [10]. Participants who lost at least 5% of body weight on open-label tirzepatide 10 mg or 15 mg over 36 weeks were then randomized to continue tirzepatide or switch to placebo for another 52 weeks. Those who continued treatment lost an additional 5.5% of body weight. Those switched to placebo regained 14.0% of body weight. The message is unambiguous: stopping tirzepatide leads to weight regain, consistent with the chronic disease model of obesity that the Endocrine Society and the Obesity Medicine Association both endorse [11].

Dr. Louis Aronne, director of the Comprehensive Weight Control Center at Weill Cornell Medicine, has described this pattern plainly: "Obesity is a chronic disease driven by biological mechanisms. Expecting medications to produce permanent weight loss after discontinuation is like expecting blood pressure to stay controlled after stopping an antihypertensive" [10].

SURMOUNT-5: Head-to-Head Against Semaglutide

SURMOUNT-5 provided the first randomized, head-to-head comparison of tirzepatide and semaglutide in adults with obesity but without diabetes [12]. The open-label trial randomized 751 adults to tirzepatide (titrated to 10 mg or 15 mg) or semaglutide 2.4 mg (the Wegovy dose) for 72 weeks.

Tirzepatide produced greater weight loss. Mean body weight reduction was -20.2% with tirzepatide versus -13.7% with semaglutide, a difference of 6.5 percentage points [12]. The proportion of participants achieving at least 25% weight loss was 31.6% with tirzepatide versus 16.1% with semaglutide. This was an open-label study, which introduces potential bias, but the magnitude of the difference makes it clinically meaningful regardless of study design.

Gastrointestinal adverse events occurred at similar rates in both arms, suggesting the extra weight loss from tirzepatide does not come at the cost of proportionally worse tolerability. Serious adverse events were also comparable between groups.

SURPASS Trials: The Diabetes Evidence Base

Before the SURMOUNT program, the SURPASS trials established tirzepatide's efficacy in type 2 diabetes [13]. These five trials compared tirzepatide to placebo (SURPASS-1), semaglutide 1 mg (SURPASS-2), insulin degludec (SURPASS-3), insulin glargine (SURPASS-4), and insulin glargine in an insulin-requiring population (SURPASS-5).

SURPASS-2 is particularly relevant. In 1,879 adults with type 2 diabetes, tirzepatide 15 mg reduced HbA1c by 2.46% versus 1.86% with semaglutide 1 mg, and reduced body weight by 12.4 kg versus 6.2 kg with semaglutide [14]. This was the first large-scale hint that tirzepatide's dual agonism translated to greater weight loss than single GLP-1 agonism. The semaglutide dose used (1 mg) was the Ozempic diabetes dose, not the higher 2.4 mg Wegovy dose, so direct extrapolation to weight management required the SURMOUNT-5 data above.

Off-Label Considerations: Practical and Legal Context

Off-label prescribing of Mounjaro for weight loss is not a fringe practice. A 2024 Trilliant Health analysis estimated that roughly 40% of tirzepatide prescriptions in the United States were written for patients without a documented diabetes diagnosis [15]. The legal framework supporting off-label use is well established. The FDA regulates drug marketing, not prescribing. Physicians may prescribe any approved drug for any indication when clinical judgment supports it.

The practical reasons clinicians choose Mounjaro over Zepbound include insurance coverage arbitrage, as described above, and supply chain dynamics. During the 2023-2024 shortage periods, Mounjaro and Zepbound experienced different shortage patterns depending on dose strength and distributor [16]. Some patients found one brand available when the other was not.

Patients should be aware that using Mounjaro off-label means the prescription may not carry the specific weight-management labeling, patient medication guide, or REMS considerations that accompany Zepbound. Clinicians prescribing off-label should document the clinical rationale, discuss the evidence, and obtain informed consent.

Dosing and Titration for Weight Loss

The dose-escalation schedule for Mounjaro is identical whether prescribed on-label for diabetes or off-label for weight loss [1]. Treatment begins at 2.5 mg once weekly for 4 weeks. This starting dose is designed for tolerability, not efficacy. After 4 weeks, the dose increases to 5 mg weekly.

From 5 mg, increases of 2.5 mg every 4 weeks continue as tolerated: 5 mg to 7.5 mg to 10 mg to 12.5 mg to 15 mg. Not every patient needs to reach 15 mg. The SURMOUNT-1 data showed clinically significant weight loss at all three studied doses [6]. Some patients achieve their goals at 10 mg with fewer GI side effects. Others need the full 15 mg.

Rushing titration increases the risk of nausea and vomiting without improving long-term outcomes. The FDA label explicitly states the 2.5 mg dose is for initiation only and is not expected to provide effective glycemic control or weight loss [1]. Patients who plateau at a given dose for 8 or more weeks may benefit from dose escalation, but a plateau at 8 weeks is different from a plateau at 4 weeks. Tirzepatide takes roughly 20 weeks of dosing to reach steady state at the maximum dose. Patience during titration is not optional.

Safety Profile and Monitoring

The pooled safety data across SURMOUNT and SURPASS trials provide a comprehensive adverse-event picture. Gastrointestinal side effects dominate. Across all trials, nausea affected approximately 15% to 33% of patients on active drug, with the highest rates during dose escalation [6][8][13]. Most episodes resolved within 2 to 4 weeks at each dose level.

Pancreatitis occurred rarely: the incidence in clinical trials was <0.2% across all tirzepatide groups [1]. The FDA label carries a boxed warning about thyroid C-cell tumors based on rodent studies with GLP-1 receptor agonists, though this has not been observed in humans with tirzepatide [1]. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Gallbladder-related events (cholelithiasis, cholecystitis) occurred in 0.6% to 1.6% of tirzepatide-treated patients across SURMOUNT trials versus 0.4% with placebo, consistent with the known association between rapid weight loss and gallstone formation [6][8].

Monitoring during treatment should include periodic assessment of GI tolerability, injection site reactions, heart rate (tirzepatide increases resting heart rate by 2 to 4 bpm on average), and renal function in patients with pre-existing kidney disease [1]. For patients using Mounjaro off-label who do not have diabetes, routine blood glucose and HbA1c monitoring is not strictly required but may be informative, as tirzepatide can cause hypoglycemia in patients on concomitant insulin or sulfonylureas.

Who Should Not Use Tirzepatide Off-Label

Certain populations should not receive off-label tirzepatide for weight management. Patients with a BMI below 27 without weight-related comorbidities fall outside the evidence base from SURMOUNT trials [6]. Pregnant or breastfeeding patients should not use tirzepatide, as the drug showed embryofetal toxicity in animal studies, and the label recommends discontinuing at least 2 months before a planned pregnancy given the drug's long half-life [1].

Patients with a history of pancreatitis require careful risk-benefit discussion. Those with severe gastroparesis or active gallbladder disease may find their conditions worsened by GLP-1 receptor agonism. Patients with a history of medullary thyroid carcinoma or MEN2 have an absolute contraindication [1].

The evidence does not support tirzepatide use in adolescents for weight management outside of clinical trials, though pediatric studies are ongoing. The Endocrine Society's 2024 clinical practice guideline on pharmacotherapy for obesity recommends GLP-1 receptor agonists as first- or second-line options in adults but notes that pediatric data remain limited [11].